Results 111 to 120 of about 2,763 (183)

Post-marketing safety of CGRP monoclonal antibodies and gepants: A systematic review of spontaneous reporting system data. [PDF]

Headache
Giacon M, Terrazzino S.
europepmc   +1 more source

Effect of Erenumab on Patient-Reported Outcomes in Episodic Migraine in Asia, the Middle East, and Latin America: Results From the EMPOwER Study. [PDF]

Neurol Clin Pract
Wang SJ, Roxas AA, Saravia B, Kim BK, Chowdhury D, Riachi NJ, Tai MS, Tanprawate S, Tran TN, Zhao YJ, Su W, Wen S, Mondal S, Ecochard L, Arkuszewski M.   +14 more
europepmc   +1 more source

Effects of erenumab on migraine aura frequency: a REFORM study. [PDF]

J Headache Pain
Jakobsen JT, Karlsson WK, Christensen RH, Al-Khazali HM, Ashina M, Ashina H.   +5 more
europepmc   +1 more source

Retrospective Review of Dual CGRP-Targeted Regimens for Acute and Preventive Treatment of Migraines in a Veteran Population. [PDF]

Fed Pract
Forrest A, Billow D, Martin A.
europepmc   +1 more source

Migraine, monoclonal antibodies, and monitoring: a review of pharmacovigilance in the era of biologics. [PDF]

Front Pharmacol
Guarnieri L, Bosco F, Corasaniti MT, Citraro R, De Sarro G.   +4 more
europepmc   +1 more source

Prescriber adherence to treatment guidelines for monoclonal antibodies against Calcitonin Gene-Related Peptide in migraine prophylaxis - a register-based cohort study. [PDF]

J Headache Pain
Nordenmalm S, Malmström RE, Freyland S, Nilsson Remahl AIM, Wirdefeldt K, Ekheden I.   +5 more
europepmc   +1 more source

Comparing the Efficacy and Safety of Anti-CGRP Monoclonal Antibodies Versus Topiramate for Migraine Prophylaxis: Six-Month, Real-World, Intention-to-Treat Retrospective Evidence from the GRASP Study Group. [PDF]

Neurol Int
Vikelis M, Rikos D, Argyriou AA, Soldatos P, Tsironis C, Giakoumakis E, Xiromerisiou G, Chondrogianni M, Foska A, Koutsokera M, Notas K, Mavraki E, Dermitzakis EV, Greek Research Alliance for the Study of Headache and Pain (GRASP) Study Group.   +13 more
europepmc   +1 more source

Multiple Sclerosis With Migraine and Pyoderma Gangrenosum Treated With Ofatumumab and Erenumab. [PDF]

Cureus
Motegi H, Komatsu T, Onda A, Sakai K, Iguchi Y.   +4 more
europepmc   +1 more source

Chronic migraine management with onabotulinumtoxinA and anti-CGRP/R monoclonal antibodies in an Italian real-world setting: update on therapeutic appropriateness and an emerging role of pharmacy. [PDF]

Front Pharmacol
Scuteri D, Naturale MD, Pagliaro M, Brescia A, De Francesco AE, Lawrence GW, Bagetta G, Corasaniti MT.   +7 more
europepmc   +1 more source

Drugs for Migraine Prophylaxis. [PDF]

Dtsch Arztebl Int
Diener HC, Grans J, Reuter U.
europepmc   +1 more source